Mistletoe / Iscador
Viscum album
Mistletoe is the most widely used complementary cancer therapy in Europe, with 100+ clinical studies. Lectins and viscotoxins selectively induce apoptosis in cancer cells. Multiple studies confirm improved quality of life, reduced chemo side effects, enhanced NK cell activity, and potential survival benefit in breast, colon, lung, and ovarian cancers.
Medicinal Properties
Cancer Types Studied
Recommended Dosage
Must be prescribed by trained integrative oncologist. Subcutaneous injection (Iscador/Helixor) 2–3 times per week.
Preparations
Subcutaneous Injection (Clinical)
Iscador, Helixor, or Eurixor injected subcutaneously by trained practitioner. Dose titrated based on patient response.
NIH / PubMed Research
Links open on PubMed (National Library of Medicine). Research is ongoing — results may not reflect clinical use.
Cautions & Interactions
- Must be prescribed and administered by a trained integrative oncologist
- Injectable forms can cause local reactions and fever
- Avoid in primary brain tumours — lectin sensitivity
- Contraindicated in certain haematological malignancies
Related Herbs
Informational only. Not medical advice. Consult your healthcare provider before use.